1. Home
  2. AKRO vs BANR Comparison

AKRO vs BANR Comparison

Compare AKRO & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • BANR
  • Stock Information
  • Founded
  • AKRO 2017
  • BANR 1890
  • Country
  • AKRO United States
  • BANR United States
  • Employees
  • AKRO N/A
  • BANR N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • BANR Major Banks
  • Sector
  • AKRO Health Care
  • BANR Finance
  • Exchange
  • AKRO Nasdaq
  • BANR Nasdaq
  • Market Cap
  • AKRO 2.8B
  • BANR 2.3B
  • IPO Year
  • AKRO 2019
  • BANR 1995
  • Fundamental
  • Price
  • AKRO $37.63
  • BANR $60.49
  • Analyst Decision
  • AKRO Strong Buy
  • BANR Buy
  • Analyst Count
  • AKRO 9
  • BANR 6
  • Target Price
  • AKRO $76.29
  • BANR $73.80
  • AVG Volume (30 Days)
  • AKRO 1.3M
  • BANR 273.5K
  • Earning Date
  • AKRO 05-09-2025
  • BANR 04-16-2025
  • Dividend Yield
  • AKRO N/A
  • BANR 3.17%
  • EPS Growth
  • AKRO N/A
  • BANR 5.82
  • EPS
  • AKRO N/A
  • BANR 5.09
  • Revenue
  • AKRO N/A
  • BANR $614,045,000.00
  • Revenue This Year
  • AKRO N/A
  • BANR N/A
  • Revenue Next Year
  • AKRO N/A
  • BANR $5.69
  • P/E Ratio
  • AKRO N/A
  • BANR $11.89
  • Revenue Growth
  • AKRO N/A
  • BANR 3.98
  • 52 Week Low
  • AKRO $17.86
  • BANR $42.00
  • 52 Week High
  • AKRO $58.40
  • BANR $78.05
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 43.61
  • BANR 46.98
  • Support Level
  • AKRO $36.46
  • BANR $54.82
  • Resistance Level
  • AKRO $39.13
  • BANR $60.99
  • Average True Range (ATR)
  • AKRO 3.04
  • BANR 3.24
  • MACD
  • AKRO 0.06
  • BANR 0.20
  • Stochastic Oscillator
  • AKRO 57.38
  • BANR 60.39

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

Share on Social Networks: